Why the CEO of ​Agenus says its cancer trial failure is no big deal

The CEO of Lexington drugmaker Agenus on Wednesday said the market's reaction to the failure of a mid-stage trial of a potential cancer drug was overblown, and doesn't mean the drug won't work in other trials. Agenus (Nasdaq: AGEN) disclosed in a federal filing Tuesday night that a Phase 2 trial of its Prophage vaccine in combination with Genentech’s cancer drug Avastin was likely futile. An interim analysis found that the survival rate of patients with brain tumors appeared no better than the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news